



Bortezomib

Data Sheet

Catalog Number:	MC11074	Product Type:	Small Molecule
Bio-Activity:	Proteasome inhibitor	CAS #:	179324-69-7
Research Categories:	Ubiquitin/proteasome, angiogenesis, cancer	Chemical Name:	N-(2-Pyrazine)carbonyl-L-phenylalanine-L-leucine boronic acid
Solubility:	Soluble in DMSO (up to 50 mg/ml) or in Ethanol (up to 35 mg/ml).	Molecular Formula:	C19H25BN4O4
Purity:	> 98%	Molecular Weight:	384.2
Format:	Powder	Ship Temp:	Ambient
Storage:	-20°C		

Application Notes

Description/Data:

Potent and selective proteasome inhibitor ($K_i=0.6$ nM) [1]. Inhibits proliferation of a number of tumor cell lines ($IC_{50}=7$ nM) [2]. Inhibits TNF α synthesis and FGF-induced angiogenesis. Clinically useful agent for treatment of multiple myeloma [3]. Shows promise in the treatment of neurodegenerative diseases in which low-expressing proteins such as IKAP/hELP1 in familial dysautonomia are preserved [4]. Reversible. Cell permeable.

References:

- 1) J Adams et al. Cancer Res. 1999 59:2615
- 2) S Williams et al. Mol. Cancer Ther. 2003 2:835
- 3) PG Richardson et al. Cancer Control. 2003 10:361
- 4) M Herve and EC Ibrahim Neurobiol. Dis. 2017 103:113

FOR RESEARCH USE ONLY

NEUROMICS' REAGENTS ARE FOR IN VITRO AND CERTAIN NON-HUMAN IN VIVO EXPERIMENTAL USE ONLY AND NOT INTENDED FOR USE IN ANY HUMAN CLINICAL INVESTIGATION, DIAGNOSIS, PROGNOSIS, OR TREATMENT. THE ABOVE ANALYSES ARE MERELY TYPICAL GUIDES. THEY ARE NOT TO BE CONSTRUED AS BEING SPECIFICATIONS. ALL OF THE ABOVE INFORMATION IS, TO THE BEST OF OUR KNOWLEDGE, TRUE AND ACCURATE. HOWEVER, SINCE THE CONDITIONS OF USE ARE BEYOND OUR CONTROL, ALL RECOMMENDATIONS OR SUGGESTIONS ARE MADE WITHOUT GUARANTEE, EXPRESS OR IMPLIED, ON OUR PART. WE DISCLAIM ALL LIABILITY IN CONNECTION WITH THE USE OF THE INFORMATION CONTAINED HEREIN OR OTHERWISE, AND ALL SUCH RISKS ARE ASSUMED BY THE USER. WE FURTHER EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.-V2/08/2012